Loading...
•
Dec 31, 2025
Esperion Q4 2025 Earnings Report
Esperion reported strong Q4 2025 revenue growth and returned to profitability driven by collaboration revenue and continued U.S. product sales expansion.
Key Takeaways
Esperion delivered significant year-over-year revenue growth in Q4 2025, primarily driven by collaboration revenue including a milestone payment and growing U.S. product sales, resulting in strong operating income and net profitability for the quarter.
Total Q4 revenue reached 168446000, representing 144% year-over-year growth.
U.S. net product revenue increased to 43723000 with approximately 38% year-over-year growth.
Collaboration revenue surged to 124723000, driven by a milestone payment and royalty growth.
The company generated 61831000 in net income and 85233000 in operating income during the quarter.
Revenue by Segment
Forward Guidance
Esperion expects increased investment and operating expenses in 2026 as it expands commercialization and advances its pipeline while continuing to grow its cardiovascular franchise.
Positive Outlook
- Strong U.S. commercial momentum for the bempedoic acid franchise.
- Global expansion through partnerships across Europe, Japan, and other regions.
- Pipeline development including triple combination therapies targeting LDL-C reduction.
- Strategic acquisition of Corstasis Therapeutics expected to expand cardiovascular portfolio.
- Royalty revenue growth from international partners.
Challenges Ahead
- Expected 2026 operating expenses projected between 225000000 and 255000000.
- Higher commercial and marketing investments to support growth.
- Revenue volatility tied to milestone payments from partners.
- Dependence on partner commercialization performance in global markets.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...